|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2005-12-29
|
|
pubmed:abstractText |
Although intravenous (IV) fludarabine phosphate is effective against indolent B-cell non-Hodgkin's lymphoma (B-NHL), IV administration for 3 to 5 consecutive days is inconvenient in an outpatient setting. To assess the efficacy and toxicity of oral fludarabine phosphate in patients with indolent B-NHL, we conducted a multicenter phase II study.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:HayashiMasakiM,
pubmed-author:HottaTomomitsuT,
pubmed-author:IshizawaKen-ichiK,
pubmed-author:MatsunoYoshihiroY,
pubmed-author:MatsusakoMasakiM,
pubmed-author:MinamiHironobuH,
pubmed-author:MoriShigeoS,
pubmed-author:MorishimaYasuoY,
pubmed-author:NakamuraShigeoS,
pubmed-author:NawanoShigeruS,
pubmed-author:OgawaYoshiakiY,
pubmed-author:OguraMichinoriM,
pubmed-author:OhashiYasuoY,
pubmed-author:SeriuTakuT,
pubmed-author:TaniwakiMasafumiM,
pubmed-author:TerauchiTakashiT,
pubmed-author:TobinaiKenseiK,
pubmed-author:UtsunomiyaAtaeA,
pubmed-author:WatanabeTakashiT
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
24
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
174-80
|
|
pubmed:meshHeading |
pubmed-meshheading:16330664-Administration, Oral,
pubmed-meshheading:16330664-Adult,
pubmed-meshheading:16330664-Aged,
pubmed-meshheading:16330664-Antimetabolites, Antineoplastic,
pubmed-meshheading:16330664-Female,
pubmed-meshheading:16330664-Humans,
pubmed-meshheading:16330664-Lymphoma, B-Cell,
pubmed-meshheading:16330664-Male,
pubmed-meshheading:16330664-Middle Aged,
pubmed-meshheading:16330664-Recurrence,
pubmed-meshheading:16330664-Vidarabine Phosphate
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin's lymphoma.
|
|
pubmed:affiliation |
Hematology and Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan. ktobinai@ncc.go.jp
|
|
pubmed:publicationType |
Journal Article,
Multicenter Study,
Clinical Trial, Phase II
|
